Hola,
¿eres nuevo aquí?

Registrate y conecta tu empresa con financiación pública, partners y proyectos.

OVCure

Financiado

Curing ovarian cancer through autoantibody-based therapy

Ovarian cancer (OC) is a malignant tumor with poor prognosis and limited treatment options, responsible for 4.4% of cancer-related mortality in women. There is an urgent need for innovative therapeutic approaches for OC. Antibody... ver más

31/01/2026

WEIZMANN

150K€

Presupuesto del proyecto: 150K€

Líder del proyecto

WEIZMANN INSTITUTE OF SCIENCE No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-02-27

Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:

ERC-2023-POC: ERC PROOF OF CONCEPT GRANTS

I+D

Cerrada hace 1 año

0% 100% 100%

1 Participantes

WEIZMANN

150.00K€ | Lider

Proyectos interesantes

SweetAim Selective glycoimmuno targeting for cancer therapy 1M€ Cerrado

MIMIC Molecular mimicry as a key parameter shaping T cell immunity 2M€ Cerrado

CPP2021-008924 NUEVOS CONJUGADOS ANTICUERPO-FÁRMACO BIESPECÍFICOS BASADOS E... 751K€ Cerrado

INCEPTOR Investigate the mode of action ofInvestigate the mode of act... 192K€ Cerrado

Mel-Immune An integrative genetic approach for the exploration of melan... 3M€ Cerrado

NeoIDC Neoantigen Identification with Dendritic Cell Reprogramming 150K€ Cerrado

Últimas noticias

29-11-2024: IDAE En las últimas 48 horas el Organismo IDAE ha otorgado 4 concesiones

29-11-2024: ECE En las últimas 48 horas el Organismo ECE ha otorgado 2 concesiones

29-11-2024: CMVAMADRID En las últimas 48 horas el Organismo CMVAMADRID ha otorgado 37 concesiones

Duración del proyecto: 23 meses Fecha Inicio: 2024-02-27
Fecha Fin: 2026-01-31

Líder del proyecto

WEIZMANN INSTITUTE OF SCIENCE

TRL 4-5

Presupuesto del proyecto 150K€

Descripción del proyecto Ovarian cancer (OC) is a malignant tumor with poor prognosis and limited treatment options, responsible for 4.4% of cancer-related mortality in women. There is an urgent need for innovative therapeutic approaches for OC. Antibody drug conjugates (ADCs) represent one of the most promising therapeutic approaches, but their efficacy has been hindered by identification of suitable tumor-associated antigens. For example, ADCs targeting MUC16, the best diagnostic marker for OC, have thus far failed in clinical trials due to shedding of MUC16 from the tumor. Our breakthrough lies in the identification and characterization of a MUC16-specific autoantibody clone – 2B5, which specifically targets the non-shed and highly conserved epitope of MUC16 that stays associated with the tumor. This consequently, dramatically increases the efficacy of the cytotoxic payload delivery to the tumor, and overcomes limitations of similar ADCs that have failed in the past. By directly and selectively targeting MUC16 on OC, while sparing healthy tissues, our ADC has the potential to revolutionize OC therapy by finally offering a precise and effective ADC cancer treatment. Thus, for this PoC, we aim to demonstrate the effectivity of our 2B5-based ADC, as a leading candidate for OC therapy in humans. In order to increase its therapeutic and commercial potential, the 2B5-based ADC will be developed further to identify the most suitable payload, as well as to validate its tumor killing efficacy in pre-clinical animal models, which will be developed in frame of this project. By the end of this PoC, we aim to be ready to develop our 2B5-ADC to human grade towards phase 1 clinical trials. Simultaneously, we will define the innovation commercial feasibility and business model and will validate the business opportunities and go-to-market strategies with relevant stakeholders. Furthermore, we have already initiated the process of patenting our innovation and aim to finalize it during the PoC.

Conecta tu I+D

Entra hoy

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores